In this week’s news: new NIH money for young scientists, the future of Gilead's innovation, WHO releases updated PMTCT guidelines, correlates of protection in RV144 vaccine trial, and David Baltimore talks about new approaches to fighting HIV

• NIH announces new $20 million initiative to train early career global health researchers – The Fogarty Global Health Program for Fellows and Scholars program will provide to five consortia or academic institutions with $4 million to support training of researchers working on a variety of topics, including HIV
• Gilead and the future of HIV therapy – will the company be able to overcome the issues of expiring patents and growing competition?
• WHO updates HIV treatment guidance for pregnant women and preventing HIV infection in babies – new guidelines (pdf)  prioritize recommend starting all HIV infected pregnant women on triple ARV regimens regardless of CD4 cell count as soon as they are diagnosed with HIV
• Study explains how the first effective HIV vaccine worked – a study by Haynes et al. published in NEJM presents latest findings on correlates of protection in the RV144 HIV vaccine trial 
  • Also see NIH’s Possible clues found to why HIV vaccine showed modest protection
  • And see MHRP’s Jerome Kim explaining the results 
    

• • Nelson Michael’s presentation on “Immune Correlates of Infection Risk in the Phase 3 ALVAC-HIV/AIDSVAX-B/E Prime Boost Study: Thailand” at CROI
  • Jerome Kim’s and Bart Haynes' presentations at AIDS Vaccine 2011 in Thailand
• Danger from the wild: HIV, can we conquer it? – Nobel laureate David Baltimore’s three-part lecture on novel approaches to fight HIV and other viruses